

***Core indicators for monitoring the Ending the HIV Epidemic initiative:
National HIV Surveillance System data reported through December 2021;
and preexposure prophylaxis (PrEP) data reported through September 2021***

Advisory Statement

Effective date: May 21, 2024

Publication date of referenced document: May 2022

Preexposure prophylaxis (PrEP) coverage is currently estimated by taking the number of persons prescribed PrEP (numerator) and dividing it by the estimated number of persons with indications for PrEP (denominator). Since the current methodology for estimating PrEP coverage was first published in 2018, CDC has cited limitations of both the numerator and denominator. For example, the number of persons prescribed PrEP is estimated by using data from the IQVIA pharmacy database based on an algorithm that includes FDA-approved drugs for PrEP. Although IQVIA records 94% of all prescriptions from retail pharmacies and 74% from mail-order outlets in the United States, data from closed health care systems are not included in the IQVIA data set. Therefore, the current PrEP numerator has represented minimum estimates of PrEP prescriptions. Additionally, race/ethnicity data in the IQVIA database are only available for <40% of persons prescribed PrEP each year. Regarding limitations of the current denominator, the number of persons who have indications for PrEP is estimated by using data from 3 sources: National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Each of these data sources have different schedules of data availability. As a result, the availability of a denominator often lags the availability of a numerator.

In March 2024, updated data from 2 closed-system sources were made available to CDC that can improve the representativeness of the number of persons prescribed PrEP in the United States. In the coming months, CDC also expects to have updates to the data sets currently used to estimate the number of persons with indications for PrEP. To ensure that PrEP coverage estimates are calculated using the best available data at the time of publication, CDC is pausing PrEP coverage reporting for one year. During this time, CDC will update PrEP coverage data sources and determine the best way to present PrEP coverage. CDC plans to resume PrEP coverage reporting in the next HIV Surveillance Supplemental (Monitoring) Report, currently scheduled for publication in June 2025.

Until updated estimates are published, CDC advises against citing specific PrEP coverage data points and instead recommends referencing general trends and disparities. In addition, because of a formula error that affects a subset of race and ethnicity PrEP data, race and ethnicity data points from all reports published prior to 2024 should not be cited.

HIV | SURVEILLANCE DATA TABLES

**Core Indicators for Monitoring the Ending the
HIV Epidemic Initiative:**

**National HIV Surveillance System Data Reported
through December 2021; and Preexposure
Prophylaxis (PrEP) Data Reported through
September 2021**



Centers for Disease
Control and Prevention
National Center for HIV/AIDS,
Viral Hepatitis, STD, and
TB Prevention

This issue of *HIV Surveillance Data Tables* is published by the Division of HIV Prevention (DHP), National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, Georgia.

Data are presented for diagnoses of HIV infection reported to CDC through December 2021 and preexposure prophylaxis (PrEP) data reported through September 2021.

HIV Surveillance Data Tables is not copyrighted and may be used and copied without permission. Citation of the source is, however, appreciated.

Suggested citation

Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative: National HIV Surveillance System data reported through December 2021; and preexposure prophylaxis (PrEP) data reported through September 2021. *HIV Surveillance Data Tables* 2022;3(1). <https://www.cdc.gov/hiv/library/reports/surveillance-data-tables/>. Published May 2022. Accessed [date].

On the Web: <https://www.cdc.gov/hiv/library/reports/surveillance-data-tables/>

Confidential information, referrals, and educational material on HIV infection

CDC-INFO

1-800-232-4636 (in English, en Español)

1-888-232-6348 (TTY)

<http://wwwn.cdc.gov/dcs/ContactUs/Form>

Acknowledgments

HIV Surveillance Data Tables was prepared by the following staff and contractors of the Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC: Anna Satcher Johnson, Zanetta Gant, Ya-lin Huang, Dawn Smith, Jianmin Li, Xiaohong Hu, Baohua Wu, Kyung Lee, Pei Hou, Weiming Zhu, Lei Yu, Ishwarya Ravichandran, Saja Khader, Norma Harris, and Michael Friend (editing and desktop publishing).

The Web and Consumer Services Team of the Prevention Communications Branch are acknowledged for their contributions to the report website.

Publication of *HIV Surveillance Data Tables* was made possible by the contributions of the state and territorial health departments and the HIV surveillance programs that provided surveillance data to CDC.

Technical Notes	4
References	7
Tables	
1a Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, 2017–2021—United States	9
1b Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, 2017–2021—United States and 6 dependent areas	10
1c Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, 2017–2021—United States and 6 dependent areas	11
1d Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, 2017–2021—Ending the HIV Epidemic Phase I jurisdictions	12
2a Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥ 13 years, by selected characteristics, January 2020–September 2021—45 states and the District of Columbia	14
2b Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥ 13 years, by area of residence, January 2020–September 2021—45 states and the District of Columbia	16
2c Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥ 13 years, by area of residence, January 2020–September 2021—Ending the HIV Epidemic Phase I jurisdictions	18
3a HIV viral suppression during 2020 (COVID-19 pandemic) among persons aged ≥ 13 years with HIV infection diagnosed by year-end 2019 and alive at year-end 2020, by selected characteristics—45 states and the District of Columbia	20
3b HIV viral suppression during 2020 (COVID-19 pandemic) among persons aged ≥ 13 years with HIV infection diagnosed by year-end 2019 and alive at year-end 2020, by area of residence—45 states and the District of Columbia	21
3c HIV viral suppression during 2020 (COVID-19 pandemic) among persons aged ≥ 13 years with HIV infection diagnosed by year-end 2019 and alive at year-end 2020, by area of residence—Ending the HIV Epidemic Phase I jurisdictions	22
4a Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017 through September 2021, among persons aged ≥ 16 years, by selected characteristics—United States	24
4b Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017 through September 2021, among persons aged ≥ 16 years, by area of residence—United States and Puerto Rico	26
4c Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017 through September 2021, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions	31
5 Ending the HIV Epidemic Phase I jurisdictions	41

The *Ending the HIV Epidemic in the U.S.* (EHE) initiative leverages critical scientific advances in HIV prevention, diagnosis, treatment, and outbreak response [1]. The goal of the initiative is to reduce new HIV infections by 75% by 2025 and then by at least 90% by 2030. The 6 core indicators of the EHE initiative are the following:

- **New HIV infections:** the estimated number of new HIV infections in a calendar year.
- **Knowledge of HIV status:** the estimated percentage of persons with HIV who have received a diagnosis.
- **HIV diagnoses:** the number of HIV infections confirmed by laboratory or clinical evidence in a calendar year.
- **Linkage to HIV medical care:** the percentage of persons who have received a diagnosis of HIV infection in a calendar year and were linked to HIV medical care within 1 month.
- **HIV viral suppression:** the percentage of persons living with diagnosed HIV who have a suppressed viral load at the most recent test in a calendar year.
- **Preexposure prophylaxis (PrEP) coverage:** the percentage of the number of persons prescribed PrEP in a calendar year relative to the estimated number of persons with indications for PrEP in a calendar year.

The Centers for Disease Control and Prevention (CDC) routinely releases *HIV Surveillance Data Tables* on the core indicators for EHE to allow for more timely monitoring of progress. This release of provisional (2017–2020) and preliminary (2021) data on EHE core indicators does not include estimates of new HIV infections (HIV incidence) and knowledge of HIV status due to the impact of the COVID-19 pandemic on HIV testing in the U.S. [2–5]. CDC currently uses surveillance data and a CD4-depletion model to estimate the number of new HIV infections in the U.S. The CD4-based model cannot be used to produce reliable estimates of new infections due to COVID-related disruptions in HIV testing [3–6]. The overall number of HIV diagnoses among adults and adolescents in the U.S. in 2020 (30,346) was 17% lower than in 2019 (36,528) (Table 1a). The steep reduction in diagnoses in 2020 causes concern regard-

ing underdiagnosis during the COVID-19 pandemic [5]. Estimates of new HIV infections and knowledge of HIV status for the year 2020 will not be produced as more time and data are needed to accurately assess COVID-19's impact on HIV transmission in the U.S.

The tables included in this report provide data on HIV diagnoses and linkage to HIV medical care for years 2017–2021 and viral suppression data for the year 2020 reported to CDC as of December 2021, and data on PrEP coverage for years 2017–2021 reported through September 2021. Data for the 4 indicators are provided at the national, state, and county levels (EHE Phase I jurisdictions only). See Tabulation and Presentation of Data for details on how the indicators are calculated.

SURVEILLANCE OF HIV INFECTION

Data presented were reported (after the removal of personally identifiable information) to CDC through December 31, 2021. Please use caution when interpreting the following:

- Data on diagnoses of HIV infection. HIV surveillance reports may not be representative of all persons with HIV because not all infected persons have been (1) tested or (2) tested at a time when the infection could be detected and diagnosed. Also, some states offer anonymous HIV testing; the results of anonymous tests are not reported to the confidential, name-based HIV registries of state and local health departments. Therefore, reports of confidential test results may not represent all persons who tested positive for HIV infection.
- Deaths and prevalence-based data (HIV viral suppression).
- Numbers less than 12 and trends based on these numbers.
- Data for the year 2020. The COVID-19 pandemic may have impacted access to HIV testing and care, and case surveillance activities in state/local jurisdictions [2–5].
- Data for the year 2021. Data provided using a National HIV Surveillance System (NHSS) dataset produced prior to reaching a 12-month reporting delay are considered preliminary.

TABULATION AND PRESENTATION OF DATA

Diagnoses of HIV Infection

Diagnoses of HIV infection are the numbers of persons aged ≥ 13 years with HIV diagnosed during January 2020 through December 2021 (Tables 1a–d). Data presented were reported (after the removal of personally identifiable information) to CDC.

An evaluation of surveillance data (2015–2019 diagnoses) found that, on average, approximately 75% of HIV diagnoses are reported to CDC during the year of diagnosis and approximately 95% of HIV diagnoses are reported to CDC by the end of the following year. Data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions [2–5]. Data for the year 2021 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

More information on counting diagnoses of HIV infection can be found at <https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-33/index.html> (*HIV Surveillance Report*, 2020).

Linkage to HIV Medical Care

Linkage to HIV medical care within 1 month of HIV diagnosis is measured for persons aged ≥ 13 years whose infection was diagnosed during January 2020 through September 2021 and who resided in any of the jurisdictions (including EHE Phase I jurisdictions) with complete reporting of laboratory data to CDC at the time of diagnosis (Tables 2a–c). The numerator is the number of persons aged ≥ 13 years whose HIV infection was diagnosed during January 2020 through September 2021 and who had ≥ 1 CD4 T-lymphocyte (CD4) or viral load (VL) tests within 1 month of HIV diagnosis. The denominator is the number of persons aged ≥ 13 years whose HIV infection was diagnosed during January 2020 through September 2021. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting delay to account for delays in reporting of laboratory results to NHSS; therefore, data on linkage to HIV medical care in these surveillance tables are for persons whose HIV infection was diagnosed during January 2020 through September 2021 and was reported to NHSS through December 2021. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads, or that have

incomplete reporting of laboratory data to CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kentucky, Pennsylvania, Puerto Rico, and Vermont.

Data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions [2]. Data for the year 2021 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

More information on calculating linkage to care can be found at <https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-27-no-3/index.html> (*Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas*, 2020).

Viral Suppression

Viral suppression at most recent test during 2020 is measured for persons aged ≥ 13 years who resided, as of their most recent known address during 2020, in any of the jurisdictions (including EHE Phase I jurisdictions) with complete reporting of laboratory data to CDC, and who were alive at the end of 2020 (Tables 3a–c). The numerator is the number of persons aged ≥ 13 years with HIV infection diagnosed by the end of 2019, and who had a VL of <200 copies/mL at the most recent test in 2020. The denominator is the number of persons aged ≥ 13 years with HIV diagnosed by the end of 2019, and who were alive at the end of 2020. Data used to calculate prevalence are based on deaths reported to CDC as of December 2021. The following areas had incomplete reporting of deaths for the year 2020, and viral suppression data should be interpreted with caution: Kansas, North Carolina, Puerto Rico, and South Carolina. Data for Maryland should be interpreted with caution due to incomplete reporting of case information to CDC during December 2021. Data are not provided for states and associated EHE Phase I jurisdictions that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kentucky, Pennsylvania, Puerto Rico, and Vermont.

Data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and

case surveillance activities in state/local jurisdictions [2–5].

More information on calculating viral suppression can be found at <https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-27-no-3/index.html> (*Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2020*).

Preexposure Prophylaxis Coverage

Preexposure prophylaxis (PrEP) coverage, reported as a percentage, is defined as the number of persons aged ≥ 16 years classified as having been prescribed PrEP during the specified year divided by the estimated number of persons aged ≥ 16 years who had indications for PrEP during the specified year (Tables 4a–c). PrEP coverage is an EHE indicator that is not a reportable disease or condition and is not reported to NHSS. Multiple data sources, described below, are used to calculate PrEP coverage.

Please use caution when interpreting PrEP data. Different data sources were used in the numerator and denominator to calculate PrEP coverage.

Persons prescribed PrEP

National pharmacy data from the IQVIA Real World Data—Longitudinal Prescriptions database (hereafter, IQVIA database) are used to classify persons aged ≥ 16 years who have been prescribed PrEP in the specific year. The IQVIA database captures prescriptions from all payers and represents approximately 92% of all prescriptions from retail pharmacies and 60%–86% from mail-order outlets in the United States. The database does not include prescriptions from some closed health care systems that do not make their prescription data available to IQVIA. Therefore, these are minimum estimates of PrEP coverage. The annual number of persons classified as having been prescribed PrEP was based on a validated algorithm that discerns whether tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) was prescribed for PrEP after excluding prescriptions for HIV treatment, hepatitis B treatment, or HIV postexposure prophylaxis [7–9]. Tenofovir alafenamide and emtricitabine (TAF/FTC) was approved as an alternative drug for PrEP by the U.S. Food and Drug Administration (FDA) in October 2019. Starting with the 2019 data, TAF/FTC was included in the algorithm to classify the number of persons prescribed PrEP. In addition,

generic TDF/FTC for PrEP became available in the United States in October 2020. Starting with the 2020 data, generic TDF/FTC was included in the algorithm to classify the number of persons prescribed PrEP.

The number of persons classified as having been prescribed PrEP is reported by sex, age group, and race/ethnicity. Transmission category data are not available in the IQVIA database, and race/ethnicity data are available for $<40\%$ of persons with PrEP prescriptions. Please use caution when interpreting PrEP data by race/ethnicity. Race/ethnicity categories available in the IQVIA database include White, Black/African American, Hispanic/Latino, and other. The number of persons prescribed PrEP for each racial/ethnic group presented in this report was extrapolated by applying the racial/ethnic distribution of known records to those for which data on race/ethnicity were unknown.

Geographic designations

In the IQVIA database, a person's location is reported as a 3-digit ZIP code prefix (hereafter, ZIP3) assigned by the U.S. Postal Service. To estimate the number of persons prescribed PrEP at the state or county level, a probability-based approach is used to crosswalk between ZIP3s and states/counties by using data from (a) the U.S. Census Bureau's American Community Survey (ACS) 5-year estimates by ZIP Code Tabulation Areas (ZCTAs) [10], and (b) the U.S. Department of Housing and Urban Development's ZIP Code Crosswalk Files [11]. Because of reliability concerns, subnational estimates of <40 are not included.

Persons with PrEP indications

The ACS and U.S. Census Bureau files were used to estimate the number of men who have sex with men (MSM) in a jurisdiction [12, 13]. Next, behavioral data from the National Health and Nutrition Examination Survey (NHANES) were used to estimate the proportion of HIV-negative MSM with indications for PrEP [14].

The number of HIV-negative MSM with indications for PrEP was multiplied by the ratio of percentage of diagnoses during the specified year attributed to other major transmission risk groups compared to the percentage among MSM in a given state or county. The estimated numbers of persons with indications for PrEP in the 3 major transmission risk groups (MSM, heterosexuals, persons who inject drugs) in each juris-

diction were then summed to yield a state- or county-specific estimate. State estimates were then summed for a national total of persons with indications for PrEP [12]. Jurisdictional estimates were rounded to the nearest 10.

The tables included in this report provide updated data on PrEP coverage for the years 2017 through September 2021 by using the IQVIA data reported through September 2021. IQVIA conducts data quality assurance activities. As a result, the number of persons classified as having been prescribed PrEP in a given year might change from time to time. The impact of the changes may vary by demographic category nationally and by jurisdiction. The data sources used to estimate the number of persons with indications for PrEP have different schedules of availability. Consequently, the availability of a denominator lags the availability of a numerator by 1 year or more. PrEP coverage data with a lagged denominator are considered preliminary.

For this release of *HIV Surveillance Data Tables*, 2017 denominators were used for 2017 PrEP coverage data; 2018 denominators were used for 2018, 2019, 2020, and 2021 PrEP coverage data; consequently, 2019 through September 2021 PrEP coverage data are considered preliminary. In addition to being preliminary, data for the year 2020 through September 2021 should be interpreted with caution and with an awareness of the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions [15].

More information on calculating PrEP coverage can be found at <https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-27-no-3/index.html> (*Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2020*).

REFERENCES

1. HHS. What is *Ending the HIV Epidemic in the U.S.*? <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview>. Updated June 2, 2021. Accessed December 1, 2021.
2. CDC [Schuchat A, CDC COVID-19 Response Team]. Public health response to the initiation and spread of pandemic COVID-19 in the United States, February 24–April 21, 2020. *MMWR* 2020;69(18):551–556. doi:10.15585/mmwr.mm6918e2
3. Delaney KP, Jayanthi P, Emerson B, et al. Impact of COVID-19 on commercial laboratory testing for HIV in the United States. 2021 CROI, March 6–10, 2021. Abstract 739.
4. Moitra E, Tao J, Olsen J, et al. Impact of the COVID-19 pandemic on HIV testing rates across four geographically diverse urban centres in the United States: An observational study. *Lancet Reg Health Am* 2022;7:100159. doi:10.1016/j.lana.2021.100159
5. Chang JJ, Chen Q, Hechter RC, Dionne-Odom J, Bruxvoort K. Changes in HIV and STI testing and diagnoses during the COVID-19 pandemic. 2022 CROI, February 16, 2022. Abstract 142.
6. Song R, Hall HI, Green TA, Szwarcwald CL, Pantazis N. Using CD4 data to estimate HIV incidence, prevalence, and percent of undiagnosed infections in the United States. *J Acquir Immune Defic Syndr* 2017;74(1):3–9. doi:10.1097/QAI.0000000000001151
7. Wu H, Mendoza MC, Huang YA, Hayes T, Smith DK, Hoover KW. Uptake of HIV preexposure prophylaxis among commercially insured persons—United States, 2010–2014. *Clin Infect Dis* 2017;64(2):144–149. doi:10.1093/cid/ciw701
8. CDC [Huang YA, Zhu W, Smith DK, Harris N, Hoover KW]. HIV preexposure prophylaxis, by race and ethnicity—United States, 2014–2016. *MMWR* 2018;67(41):1147–1150. doi:10.15585/mmwr.mm6741a3
9. Furukawa NW, Smith DK, Gonzalez CJ, et al. Evaluation of algorithms used for PrEP surveillance using a reference population from New York City, July 2016–June 2018. *Public Health Rep* 2020;135(2):202–210. doi:10.1177/0033354920904085
10. U.S. Census Bureau. American Community Survey 5-year data (2009–2019). <https://www.census.gov/data/developers/data-sets/acs-5year.2019.html>. Published December 10, 2020. Accessed December 1, 2021.
11. U.S. Department of Housing and Urban Development (HUD). HUD USPS ZIP code crosswalk files. https://www.huduser.gov/portal/datasets/usps_crosswalk.html. Updated June 2021. Accessed December 1, 2021.

12. Grey JA, Bernstein KT, Sullivan PS, et al. Estimating the population sizes of men who have sex with men in US states and counties using data from the American Community Survey. *JMIR Public Health Surveill* 2016;2(1):e14. doi:10.2196/publichealth.5365
13. Purcell DW, Johnson CH, Lansky A, et al. Estimating the population size of men who have sex with men in the United States to obtain HIV and syphilis rates. *Open AIDS J* 2012;6:98–107. doi:10.2174/1874613601206010098
14. CDC [Smith DK, Van Handel M, Wolitski RJ, et al]. Vital Signs: Estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition—United States, 2015. *MMWR* 2015;64(46):1291–1295. doi:10.15585/mmwr.mm6446a4
15. Huang YA, Zhu W, Wiener J, Kourtis AP, Hall HI, Hoover KW. Impact of COVID-19 on HIV preexposure prophylaxis prescriptions in the United States—a time series analysis. *Clin Infect Dis* 2022:ciac038. doi:10.1093/cid/ciac038

Table 1a. Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, 2017–2021—United States

	2017 No.	2018 No.	2019 No.	2020 (COVID-19 pandemic) ^a No.	2021 (preliminary) ^b No.
Gender					
Male	30,414	29,690	28,918	24,242	24,863
Female	7,242	7,037	6,890	5,409	5,647
Transgender woman ^c	612	627	652	638	643
Transgender man ^c	33	48	45	40	46
Additional gender identity ^d	15	15	23	17	32
Age at diagnosis (yr)					
13–24	8,277	7,848	7,638	6,082	5,956
25–34	13,395	13,384	13,075	11,258	11,499
35–44	7,240	7,180	7,114	5,924	6,643
45–54	5,567	5,235	4,887	3,929	3,833
≥55	3,837	3,770	3,814	3,153	3,300
Race/ethnicity					
American Indian/Alaska Native	200	173	204	200	198
Asian	923	862	733	635	630
Black/African American	16,223	15,736	15,471	12,824	12,846
Hispanic/Latino ^e	9,925	9,945	9,889	7,999	8,775
Native Hawaiian/other Pacific Islander	50	61	66	65	74
White	9,628	9,433	9,063	7,831	8,110
Multiracial	1,367	1,207	1,102	792	598
Transmission category (based on sex at birth)^f					
Male-to-male sexual contact	25,346	24,545	23,975	20,572	21,230
Injection drug use					
Male	1,292	1,407	1,381	1,178	1,273
Female	1,086	1,105	1,154	855	944
Male-to-male sexual contact and injection drug use	1,470	1,465	1,524	1,105	1,099
Heterosexual contact ^g					
Male	2,902	2,877	2,669	2,012	1,895
Female	6,131	5,928	5,730	4,536	4,696
Other ^h					
Male	31	37	39	29	37
Female	58	53	54	59	59
Region of residenceⁱ					
Northeast	5,977	5,557	5,305	4,262	4,159
Midwest	5,096	4,927	4,740	4,118	4,203
South	19,662	19,364	19,149	15,661	16,740
West	7,581	7,569	7,334	6,305	6,129
Total	38,316	37,417	36,528	30,346	31,231

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are for cases reported to CDC through December 2021.

^a Data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.

^b Data for the year 2021 are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

^c “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.

^d Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

^e Hispanic/Latino persons can be of any race.

^f Transmission category is determined based on assigned sex at birth; data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column totals.

^g Sexual contact with a person known to have, or with a risk factor for, HIV infection.

^h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.

ⁱ Data are based on residence at time of diagnosis of HIV infection.

Table 1b. Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, 2017–2021—United States and 6 dependent areas

	2017 No.	2018 No.	2019 No.	2020 (COVID-19 pandemic) ^a No.	2021 (preliminary) ^b No.
Gender					
Male	30,778	30,058	29,247	24,488	25,140
Female	7,336	7,117	6,971	5,450	5,720
Transgender woman ^c	614	629	654	640	643
Transgender man ^c	33	49	45	40	46
Additional gender identity ^d	15	15	23	17	32
Age at diagnosis (yr)					
13–24	8,355	7,927	7,701	6,135	6,011
25–34	13,520	13,519	13,191	11,336	11,593
35–44	7,327	7,255	7,192	5,985	6,720
45–54	5,658	5,328	4,954	3,977	3,904
≥55	3,916	3,839	3,902	3,202	3,353
Race/ethnicity					
American Indian/Alaska Native	200	173	204	200	198
Asian	926	866	740	635	630
Black/African American	16,227	15,744	15,476	12,827	12,849
Hispanic/Latino ^e	10,371	10,377	10,280	8,285	9,117
Native Hawaiian/other Pacific Islander	51	63	70	65	74
White	9,633	9,436	9,068	7,831	8,115
Multiracial	1,368	1,209	1,102	792	598
Transmission category (based on sex at birth)^f					
Male-to-male sexual contact	25,580	24,810	24,204	20,758	21,436
Injection drug use					
Male	1,326	1,431	1,406	1,198	1,292
Female	1,095	1,107	1,160	857	947
Male-to-male sexual contact and injection drug use	1,483	1,477	1,536	1,109	1,100
Heterosexual contact ^g					
Male	2,987	2,947	2,734	2,051	1,945
Female	6,216	6,008	5,805	4,575	4,765
Other ^h					
Male	31	37	40	29	38
Female	58	53	55	59	59
Region of residenceⁱ					
Northeast	5,977	5,557	5,305	4,262	4,159
Midwest	5,096	4,927	4,740	4,118	4,203
South	19,662	19,364	19,149	15,661	16,740
West	7,581	7,569	7,334	6,305	6,129
U.S. dependent areas	460	451	412	289	350
Total	38,776	37,868	36,940	30,635	31,581

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are for cases reported to CDC through December 2021.

^a Data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.

^b Data for the year 2021 are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

^c “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.

^d Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

^e Hispanic/Latino persons can be of any race.

^f Transmission category is determined based on assigned sex at birth; data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column totals.

^g Sexual contact with a person known to have, or with a risk factor for, HIV infection.

^h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.

ⁱ Data are based on residence at time of diagnosis of HIV infection.

Table 1c. Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, 2017–2021—United States and 6 dependent areas

Area of residence	2017 No.	2018 No.	2019 No.	2020 (COVID-19 pandemic) ^a No.	2021 (preliminary) ^b No.
Alabama	647	604	635	585	386
Alaska	30	23	27	29	22
Arizona	720	752	747	662	723
Arkansas	287	286	289	242	337
California	4,839	4,749	4,454	3,924	3,535
Colorado	434	403	465	324	356
Connecticut	274	259	212	171	199
Delaware	125	91	94	93	81
District of Columbia	316	280	250	197	97
Florida	4,558	4,515	4,361	3,408	4,437
Georgia	2,606	2,486	2,407	1,977	1,689
Hawaii	76	72	64	51	58
Idaho	45	37	33	32	36
Illinois	1,372	1,369	1,257	1,096	842
Indiana	515	511	486	433	484
Iowa	125	114	100	100	120
Kansas	120	157	132	138	155
Kentucky	367	378	328	300	351
Louisiana	989	957	880	722	956
Maine	29	31	30	16	30
Maryland	1,020	990	915	706	634
Massachusetts	602	648	538	434	269
Michigan	773	719	674	519	628
Minnesota	278	286	273	229	286
Mississippi	429	475	471	402	390
Missouri	505	450	487	359	507
Montana	31	24	25	14	21
Nebraska	87	77	81	73	85
Nevada	497	497	518	392	450
New Hampshire	32	38	31	33	30
New Jersey	1,105	1,020	1,083	805	902
New Mexico	148	155	174	131	143
New York	2,736	2,449	2,336	1,963	1,844
North Carolina	1,291	1,180	1,365	1,079	1,297
North Dakota	38	36	40	36	21
Ohio	982	973	965	888	821
Oklahoma	300	278	336	333	260
Oregon	203	229	199	180	193
Pennsylvania	1,093	1,018	993	775	828
Rhode Island	86	76	71	53	51
South Carolina	708	725	722	655	525
South Dakota	41	29	33	34	24
Tennessee	721	742	773	647	782
Texas	4,356	4,425	4,342	3,548	3,623
Utah	113	120	135	131	119
Vermont	20	18	11	12	6
Virginia	865	866	833	628	764
Washington	435	496	480	421	467
West Virginia	77	86	148	139	131
Wisconsin	260	206	212	213	230
Wyoming	10	12	13	14	6
Subtotal	38,316	37,417	36,528	30,346	31,231
U.S. dependent areas					
American Samoa	0	0	0	0	0
Guam	4	7	11	0	1
Northern Mariana Islands	1	1	2	0	0
Puerto Rico	447	431	391	286	346
Republic of Palau	0	0	0	0	0
U.S. Virgin Islands	8	12	8	3	3
Subtotal	460	451	412	289	350
Total	38,776	37,868	36,940	30,635	31,581

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at diagnosis of HIV infection. Data are for cases reported to CDC through December 2021.

^a Data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.

^b Data for the year 2021 are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

Table 1d. Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, 2017–2021—Ending the HIV Epidemic Phase I jurisdictions

Area of residence	2017 No.	2018 No.	2019 No.	2020 (COVID-19 pandemic) ^a No.	2021 (preliminary) ^b No.
Arizona					
Maricopa County	493	528	505	477	489
California					
Alameda County	202	199	217	157	175
Los Angeles County	1,743	1,703	1,537	1,382	1,229
Orange County	314	288	247	264	250
Riverside County	275	263	266	239	207
Sacramento County	180	169	147	153	97
San Bernardino County	255	263	295	263	250
San Diego County	414	383	383	296	175
San Francisco County	244	239	208	153	178
District of Columbia	316	280	250	197	97
Florida					
Broward County	671	617	597	460	664
Duval County	297	275	279	229	281
Hillsborough County	300	297	265	247	333
Miami-Dade County	1,142	1,163	1,134	781	1,161
Orange County	465	454	464	369	443
Palm Beach County	287	281	236	213	168
Pinellas County	163	175	182	152	140
Georgia					
Cobb County	159	153	178	135	105
DeKalb County	366	356	343	269	240
Fulton County	619	596	532	477	456
Gwinnett County	180	148	211	149	104
Illinois					
Cook County	985	979	882	774	627
Indiana					
Marion County	226	205	205	167	199
Louisiana					
East Baton Rouge Parish	163	177	155	124	148
Orleans Parish	180	177	158	105	156
Maryland					
Baltimore City	237	231	197	175	120
Montgomery County	165	126	131	80	79
Prince George's County	303	304	278	214	194
Massachusetts					
Suffolk County	163	148	133	135	95
Michigan					
Wayne County	322	300	289	227	251
Nevada					
Clark County	449	443	451	343	403
New Jersey					
Essex County	310	259	233	199	220
Hudson County	161	162	150	123	121

Table 1d. Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, 2017–2021—Ending the HIV Epidemic Phase I jurisdictions (*cont*)

Area of residence	2017 No.	2018 No.	2019 No.	2020 (COVID-19 pandemic) ^a No.	2021 (<i>preliminary</i>) ^b No.
New York					
Bronx County	503	458	502	338	353
Kings County	629	544	474	444	368
New York County	398	375	333	296	305
Queens County	433	414	354	316	291
North Carolina					
Mecklenburg County	269	237	267	209	268
Ohio					
Cuyahoga County	148	151	159	185	152
Franklin County	222	192	215	204	160
Hamilton County	187	182	172	132	114
Pennsylvania					
Philadelphia County	510	438	445	331	304
Puerto Rico					
San Juan Municipio	112	103	88	71	77
Tennessee					
Shelby County	259	291	261	235	273
Texas					
Bexar County	349	323	331	282	306
Dallas County	818	794	748	658	710
Harris County	1,100	1,203	1,218	921	1,001
Tarrant County	304	282	312	292	280
Travis County	212	188	177	162	213
Washington					
King County	213	289	242	198	232

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at diagnosis of HIV infection. Data are for cases reported to CDC through December 2021.

^a Data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.

^b Data for the year 2021 are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

Table 2a. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by selected characteristics, January 2020–September 2021—45 states and the District of Columbia

	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
2020 (COVID-19 pandemic)^a					
Gender					
Male	22,727	18,739	82.5	3,988	17.5
Female	5,042	4,146	82.2	896	17.8
Transgender woman ^b	599	484	80.8	115	19.2
Transgender man ^b	38	35	92.1	3	7.9
Additional gender identity ^c	16	15	93.8	1	6.3
Age at diagnosis (yr)					
13–24	5,728	4,585	80.0	1,143	20.0
25–34	10,570	8,701	82.3	1,869	17.7
35–44	5,545	4,573	82.5	972	17.5
45–54	3,644	3,081	84.5	563	15.5
≥55	2,935	2,479	84.5	456	15.5
Race/ethnicity					
American Indian/Alaska Native	195	156	80.0	39	20.0
Asian	612	538	87.9	74	12.1
Black/African American	12,069	9,615	79.7	2,454	20.3
Hispanic/Latino ^d	7,498	6,380	85.1	1,118	14.9
Native Hawaiian/other Pacific Islander	63	54	85.7	9	14.3
White	7,256	6,066	83.6	1,190	16.4
Multiracial	729	610	83.7	119	16.3
Transmission category (based on sex at birth)^e					
Male-to-male sexual contact	19,414	16,097	82.9	3,317	17.1
Injection drug use	1,846	1,439	77.9	407	22.1
Male	1,052	819	77.8	234	22.2
Female	794	620	78.1	174	21.9
Male-to-male sexual contact and injection drug use	1,023	821	80.3	202	19.7
Heterosexual contact ^f	6,058	4,994	82.4	1,064	17.6
Male	1,826	1,479	81.0	347	19.0
Female	4,231	3,515	83.1	717	16.9
Total^g	28,422	23,419	82.4	5,003	17.6

Table 2a. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by selected characteristics, January 2020–September 2021—45 states and the District of Columbia (*cont*)

	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
2021 (January–September, <i>preliminary</i>)^h					
Gender					
Male	19,466	16,242	83.4	3,224	16.6
Female	4,281	3,547	82.9	734	17.1
Transgender woman ^b	517	433	83.8	84	16.2
Transgender man ^b	41	38	92.7	3	7.3
Additional gender identity ^c	24	20	83.3	4	16.7
Age at diagnosis (yr)					
13–24	4,719	3,823	81.0	896	19.0
25–34	8,999	7,496	83.3	1,503	16.7
35–44	5,135	4,301	83.8	834	16.2
45–54	2,962	2,516	84.9	446	15.1
≥55	2,514	2,144	85.3	370	14.7
Race/ethnicity					
American Indian/Alaska Native	168	142	84.5	26	15.5
Asian	482	432	89.6	50	10.4
Black/African American	10,010	8,131	81.2	1,879	18.8
Hispanic/Latino ^d	6,912	5,954	86.1	958	13.9
Native Hawaiian/other Pacific Islander	51	41	80.4	10	19.6
White	6,228	5,177	83.1	1,051	16.9
Multiracial	478	403	84.3	75	15.7
Transmission category (based on sex at birth)^e					
Male-to-male sexual contact	16,726	14,033	83.9	2,692	16.1
Injection drug use	1,650	1,271	77.0	379	23.0
Male	949	720	75.9	229	24.1
Female	701	550	78.6	150	21.4
Male-to-male sexual contact and injection drug use	870	706	81.1	164	18.9
Heterosexual contact ^f	5,015	4,212	84.0	803	16.0
Male	1,432	1,211	84.6	220	15.4
Female	3,583	3,001	83.8	582	16.2
Total^g	24,329	20,280	83.4	4,049	16.6

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at diagnosis of HIV infection. Data are for cases reported to CDC through December 2021. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting delay to account for delays in reporting of laboratory results to CDC; therefore, data on linkage to HIV medical care in these surveillance tables are for persons with HIV diagnosed during January 2020 through September 2021 and reported to CDC through December 2021. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kentucky, Pennsylvania (excluding Philadelphia), and Vermont.

^a Data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.

^b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.

^c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

^d Hispanic/Latino persons can be of any race.

^e Transmission category is determined based on assigned sex at birth; data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column totals.

^f Sexual contact with a person known to have, or with a risk factor for, HIV infection.

^g Includes persons whose infection was attributed to hemophilia, blood transfusion, or perinatal exposure or whose risk factor was not reported or not identified; data not displayed because the numbers were too small to be meaningful.

^h Data for the year 2021 are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

Table 2b. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2020–September 2021—45 states and the District of Columbia

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	2020 (COVID-19 pandemic) ^a				
Alabama	585	466	79.7	119	20.3
Alaska	29	28	96.6	1	3.4
Arizona	662	561	84.7	101	15.3
Arkansas	242	193	79.8	49	20.2
California	3,924	3,269	83.3	655	16.7
Colorado	324	284	87.7	40	12.3
Connecticut	171	143	83.6	28	16.4
Delaware	93	75	80.6	18	19.4
District of Columbia	197	172	87.3	25	12.7
Florida	3,408	2,863	84.0	545	16.0
Georgia	1,977	1,605	81.2	372	18.8
Hawaii	51	44	86.3	7	13.7
Illinois	1,096	921	84.0	175	16.0
Indiana	433	323	74.6	110	25.4
Iowa	100	90	90.0	10	10.0
Kansas	138	118	85.5	20	14.5
Louisiana	722	549	76.0	173	24.0
Maine	16	15	93.8	1	6.3
Maryland	706	617	87.4	89	12.6
Massachusetts	434	382	88.0	52	12.0
Michigan	519	438	84.4	81	15.6
Minnesota	229	206	90.0	23	10.0
Mississippi	402	294	73.1	108	26.9
Missouri	359	285	79.4	74	20.6
Montana	14	13	92.9	1	7.1
Nebraska	73	65	89.0	8	11.0
Nevada	392	338	86.2	54	13.8
New Hampshire	33	26	78.8	7	21.2
New Mexico	131	111	84.7	20	15.3
New York	1,963	1,685	85.8	278	14.2
North Carolina	1,079	887	82.2	192	17.8
North Dakota	36	31	86.1	5	13.9
Ohio	888	761	85.7	127	14.3
Oklahoma	333	253	76.0	80	24.0
Oregon	180	150	83.3	30	16.7
Rhode Island	53	48	90.6	5	9.4
South Carolina	655	576	87.9	79	12.1
South Dakota	34	29	85.3	5	14.7
Tennessee	647	481	74.3	166	25.7
Texas	3,548	2,731	77.0	817	23.0
Utah	131	111	84.7	20	15.3
Virginia	628	512	81.5	116	18.5
Washington	421	373	88.6	48	11.4
West Virginia	139	99	71.2	40	28.8
Wisconsin	213	185	86.9	28	13.1
Wyoming	14	13	92.9	1	7.1

Table 2b. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2020–September 2021—45 states and the District of Columbia (*cont*)

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	2021 (January–September, <i>preliminary</i>) ^b				
Alabama	350	273	78.0	77	22.0
Alaska	17	17	100	0	0.0
Arizona	663	568	85.7	95	14.3
Arkansas	274	216	78.8	58	21.2
California	3,028	2,552	84.3	476	15.7
Colorado	301	264	87.7	37	12.3
Connecticut	171	149	87.1	22	12.9
Delaware	60	50	83.3	10	16.7
District of Columbia	90	75	83.3	15	16.7
Florida	3,496	2,991	85.6	505	14.4
Georgia	1,495	1,285	86.0	210	14.0
Hawaii	50	43	86.0	7	14.0
Illinois	745	649	87.1	96	12.9
Indiana	390	301	77.2	89	22.8
Iowa	94	82	87.2	12	12.8
Kansas	120	108	90.0	12	10.0
Louisiana	720	582	80.8	138	19.2
Maine	25	22	88.0	3	12.0
Maryland	570	507	88.9	63	11.1
Massachusetts	251	233	92.8	18	7.2
Michigan	498	438	88.0	60	12.0
Minnesota	220	182	82.7	38	17.3
Mississippi	324	227	70.1	97	29.9
Missouri	407	315	77.4	92	22.6
Montana	14	13	92.9	1	7.1
Nebraska	78	67	85.9	11	14.1
Nevada	392	350	89.3	42	10.7
New Hampshire	27	27	100	0	0.0
New Mexico	107	94	87.9	13	12.1
New York	1,568	1,350	86.1	218	13.9
North Carolina	1,046	851	81.4	195	18.6
North Dakota	21	18	85.7	3	14.3
Ohio	710	606	85.4	104	14.6
Oklahoma	223	163	73.1	60	26.9
Oregon	148	112	75.7	36	24.3
Rhode Island	50	24	48.0	26	52.0
South Carolina	500	446	89.2	54	10.8
South Dakota	23	20	87.0	3	13.0
Tennessee	624	428	68.6	196	31.4
Texas	3,061	2,426	79.3	635	20.7
Utah	99	84	84.8	15	15.2
Virginia	618	502	81.2	116	18.8
Washington	364	323	88.7	41	11.3
West Virginia	107	79	73.8	28	26.2
Wisconsin	187	165	88.2	22	11.8
Wyoming	3	3	100	0	0.0

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at diagnosis of HIV infection. Data are for cases reported to CDC through December 2021. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting delay to account for delays in reporting of laboratory results to CDC; therefore, data on linkage to HIV medical care in these surveillance tables are for persons with HIV diagnosed during January 2020 through September 2021 and reported to CDC through December 2021. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kentucky, Pennsylvania, Puerto Rico, and Vermont.

^a Data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.

^b Data for the year 2021 are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

Table 2c. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2020–September 2021—Ending the HIV Epidemic Phase I jurisdictions

Area of residence	2020 (COVID-19 pandemic) ^a					2021 (January–September, <i>preliminary</i>) ^b				
	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test		Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%	No.	No.	%	No.	%
Arizona										
Maricopa County	477	408	85.5	69	14.5	439	382	87.0	57	13.0
California										
Alameda County	157	132	84.1	25	15.9	138	125	90.6	13	9.4
Los Angeles County	1,382	1,128	81.6	254	18.4	1,052	881	83.7	171	16.3
Orange County	264	237	89.8	27	10.2	211	185	87.7	26	12.3
Riverside County	239	196	82.0	43	18.0	185	141	76.2	44	23.8
Sacramento County	153	135	88.2	18	11.8	91	81	89.0	10	11.0
San Bernardino County	263	186	70.7	77	29.3	225	169	75.1	56	24.9
San Diego County	296	256	86.5	40	13.5	162	143	88.3	19	11.7
San Francisco County	153	144	94.1	9	5.9	144	137	95.1	7	4.9
District of Columbia	197	172	87.3	25	12.7	90	75	83.3	15	16.7
Florida										
Broward County	460	402	87.4	58	12.6	506	437	86.4	69	13.6
Duval County	229	184	80.3	45	19.7	226	184	81.4	42	18.6
Hillsborough County	247	209	84.6	38	15.4	248	213	85.9	35	14.1
Miami-Dade County	781	660	84.5	121	15.5	905	785	86.7	120	13.3
Orange County	369	318	86.2	51	13.8	385	322	83.6	63	16.4
Palm Beach County	213	170	79.8	43	20.2	164	135	82.3	29	17.7
Pinellas County	152	128	84.2	24	15.8	109	89	81.7	20	18.3
Georgia										
Cobb County	135	110	81.5	25	18.5	94	85	90.4	9	9.6
DeKalb County	269	224	83.3	45	16.7	216	193	89.4	23	10.6
Fulton County	477	401	84.1	76	15.9	401	348	86.8	53	13.2
Gwinnett County	149	111	74.5	38	25.5	87	78	89.7	9	10.3
Illinois										
Cook County	774	662	85.5	112	14.5	556	485	87.2	71	12.8
Indiana										
Marion County	167	128	76.6	39	23.4	171	134	78.4	37	21.6
Louisiana										
East Baton Rouge Parish	124	99	79.8	25	20.2	117	91	77.8	26	22.2
Orleans Parish	105	84	80.0	21	20.0	106	96	90.6	10	9.4
Maryland										
Baltimore City	175	150	85.7	25	14.3	108	99	91.7	9	8.3
Montgomery County	80	70	87.5	10	12.5	73	67	91.8	6	8.2
Prince George's County	214	193	90.2	21	9.8	176	149	84.7	27	15.3
Massachusetts										
Suffolk County	135	121	89.6	14	10.4	88	84	95.5	4	4.5

Table 2c. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2020–September 2021—Ending the HIV Epidemic Phase I jurisdictions (cont)

Area of residence	2020 (COVID-19 pandemic) ^a					2021 (January–September, <i>preliminary</i>) ^b				
	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test		Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%	No.	No.	%	No.	%
Michigan										
Wayne County	227	186	81.9	41	18.1	198	172	86.9	26	13.1
Nevada										
Clark County	343	295	86.0	48	14.0	349	311	89.1	38	10.9
New York										
Bronx County	338	289	85.5	49	14.5	301	268	89.0	33	11.0
Kings County	444	376	84.7	68	15.3	317	272	85.8	45	14.2
New York County	296	250	84.5	46	15.5	258	210	81.4	48	18.6
Queens County	316	279	88.3	37	11.7	246	211	85.8	35	14.2
North Carolina										
Mecklenburg County	209	173	82.8	36	17.2	222	186	83.8	36	16.2
Ohio										
Cuyahoga County	185	164	88.6	21	11.4	123	110	89.4	13	10.6
Franklin County	204	180	88.2	24	11.8	144	128	88.9	16	11.1
Hamilton County	132	115	87.1	17	12.9	100	92	92.0	8	8.0
Pennsylvania										
Philadelphia County	331	286	86.4	45	13.6	258	212	82.2	46	17.8
Tennessee										
Shelby County	235	158	67.2	77	32.8	215	120	55.8	95	44.2
Texas										
Bexar County	282	202	71.6	80	28.4	256	202	78.9	54	21.1
Dallas County	658	502	76.3	156	23.7	573	448	78.2	125	21.8
Harris County	921	698	75.8	223	24.2	845	651	77.0	194	23.0
Tarrant County	292	211	72.3	81	27.7	252	199	79.0	53	21.0
Travis County	162	130	80.2	32	19.8	162	136	84.0	26	16.0
Washington										
King County	198	177	89.4	21	10.6	178	157	88.2	21	11.8

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at diagnosis of HIV infection. Data are for cases reported to CDC through December 2021, are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting delay to account for delays in reporting of laboratory results to CDC; therefore, data on linkage to HIV medical care in these surveillance tables are for persons with HIV diagnosed during January 2020 through September 2021 and reported to CDC through December 2021. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kentucky, Pennsylvania (excluding Philadelphia), Puerto Rico, and Vermont.

^a Data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.

^b Data for the year 2021 are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

Table 3a. HIV viral suppression during 2020 (COVID-19 pandemic) among persons aged ≥ 13 years with HIV infection diagnosed by year-end 2019 and alive at year-end 2020, by selected characteristics—45 states and the District of Columbia

	Persons alive at year-end 2020	VL <200 copies/mL	
	No.	No.	%
Gender			
Male	717,879	466,295	65.0
Female	215,092	135,941	63.2
Transgender male-to-female ^a	10,625	6,967	65.6
Transgender female-to-male ^a	444	303	68.2
Additional gender identity ^b	207	148	71.5
Age at year-end 2019 (yr)			
13–24	28,697	18,236	63.5
25–34	150,764	93,549	62.0
35–44	178,445	111,292	62.4
45–54	243,064	159,138	65.5
≥55	343,277	227,439	66.3
Race/ethnicity			
American Indian/Alaska Native	2,988	1,844	61.7
Asian ^c	14,655	9,987	68.1
Black/African American	382,521	230,853	60.4
Hispanic/Latino ^d	220,065	139,001	63.2
Native Hawaiian/other Pacific Islander	845	545	64.5
White	275,950	193,780	70.2
Multiracial	46,546	33,597	72.2
Transmission category (based on sex at birth)^e			
Male-to-male sexual contact	544,758	366,068	67.2
Injection drug use	97,081	53,638	55.3
Male	55,700	28,955	52.0
Female	41,380	24,683	59.6
Male-to-male sexual contact and injection drug use	51,989	33,360	64.2
Heterosexual contact ^f	236,672	148,910	62.9
Male	69,303	41,204	59.5
Female	167,368	107,706	64.4
Other ^g	13,748	7,677	55.8
Male	6,932	3,803	54.9
Female	6,817	3,874	56.8
Total^h	944,247	609,654	64.6

Abbreviations: VL, viral load (copies/mL); CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only]; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on address of residence as of December 31, 2020 (i.e., most recent known address). A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2020. Data not provided for states and associated jurisdictions that lack laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete lab reporting: Kentucky, Pennsylvania (excluding Philadelphia), and Vermont.

^a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender.

“Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.

^b Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

^c Includes Asian/Pacific Islander legacy cases.

^d Hispanic/Latino persons can be of any race.

^e Transmission category is determined based on assigned sex at birth; data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column total.

^f Sexual contact with a person known to have, or with a risk factor for, HIV infection.

^g Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.

^h Includes 677 persons of unknown race/ethnicity.

Table 3b. HIV viral suppression during 2020 (COVID-19 pandemic) among persons aged ≥ 13 years with HIV infection diagnosed by year-end 2019 and alive at year-end 2020, by area of residence—45 states and the District of Columbia

Area of residence	Persons alive at year-end 2020	VL <200 copies/mL	
	No.	No.	%
Alabama	13,579	8,875	65.4
Alaska	701	550	78.5
Arizona	17,060	11,242	65.9
Arkansas	5,821	2,885	49.6
California	130,455	85,115	65.2
Colorado	12,928	7,512	58.1
Connecticut	10,402	7,418	71.3
Delaware	3,349	2,405	71.8
District of Columbia	13,596	7,444	54.8
Florida	111,231	74,884	67.3
Georgia	55,634	33,659	60.5
Hawaii	2,330	1,776	76.2
Illinois	34,712	22,449	64.7
Indiana	11,440	7,493	65.5
Iowa	2,836	2,248	79.3
Kansas ^a	3,213	2,324	72.3
Louisiana	20,676	13,895	67.2
Maine	1,635	1,266	77.4
Maryland ^b	32,715	20,335	62.2
Massachusetts	20,602	13,685	66.4
Michigan	16,352	11,342	69.4
Minnesota	8,771	5,858	66.8
Mississippi	9,326	5,156	55.3
Missouri	12,511	8,108	64.8
Montana	671	517	77.0
Nebraska	2,248	1,357	60.4
Nevada	10,656	6,818	64.0
New Hampshire	1,296	951	73.4
New Mexico	3,811	2,176	57.1
New York	123,315	77,805	63.1
North Carolina ^a	32,498	21,291	65.5
North Dakota	490	330	67.3
Ohio	22,818	14,775	64.8
Oklahoma	6,281	3,696	58.8
Oregon	7,164	5,597	78.1
Rhode Island	2,615	1,812	69.3
South Carolina ^a	17,283	12,434	71.9
South Dakota	660	313	47.4
Tennessee	17,572	11,841	67.4
Texas	93,839	56,378	60.1
Utah	3,132	2,142	68.4
Virginia	23,425	14,683	62.7
Washington	13,877	10,697	77.1
West Virginia	1,951	1,175	60.2
Wisconsin	6,428	4,718	73.4
Wyoming	342	224	65.5

Abbreviations: VL, viral load (copies/mL); CD4, CD4+ T-lymphocyte count (cells/ μ L) or percentage [footnotes only]; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on address of residence as of December 31, 2020 (i.e., most recent known address). A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2020. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete lab reporting: Kentucky, Pennsylvania, Puerto Rico, and Vermont.

^a Data should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2020.

^b Data should be interpreted with caution due to incomplete reporting of case information to CDC during December 2021.

Table 3c. HIV viral suppression during 2020 (COVID-19 pandemic) among persons aged ≥ 13 years with HIV infection diagnosed by year-end 2019 and alive at year-end 2020, by area of residence—Ending the HIV Epidemic Phase I jurisdictions

Area of residence	Persons alive at year-end 2020	VL <200 copies/mL	
	No.	No.	%
Arizona			
Maricopa County	11,643	7,851	67.4
California			
Alameda County	5,883	4,117	70.0
Los Angeles County	48,881	30,955	63.3
Orange County	6,835	4,269	62.5
Riverside County	9,530	7,298	76.6
Sacramento County	4,364	2,993	68.6
San Bernardino County	4,596	2,773	60.3
San Diego County	13,026	7,687	59.0
San Francisco County	11,650	8,424	72.3
District of Columbia	13,596	7,444	54.8
Florida			
Broward County	19,525	13,410	68.7
Duval County	6,111	3,953	64.7
Hillsborough County	6,988	5,106	73.1
Miami-Dade County	25,779	15,256	59.2
Orange County	8,617	6,118	71.0
Palm Beach County	7,830	5,034	64.3
Pinellas County	4,678	3,582	76.6
Georgia			
Cobb County	3,347	2,153	64.3
DeKalb County	8,728	5,417	62.1
Fulton County	15,528	9,375	60.4
Gwinnett County	3,039	1,989	65.4
Illinois			
Cook County	25,183	16,001	63.5
Indiana			
Marion County	4,625	3,128	67.6
Louisiana			
East Baton Rouge Parish	3,977	2,967	74.6
Orleans Parish	4,845	3,233	66.7
Maryland^a			
Baltimore City	9,762	5,786	59.3
Montgomery County	3,776	2,089	55.3
Prince George's County	7,867	4,993	63.5
Massachusetts			
Suffolk County	5,571	3,673	65.9
Michigan			
Wayne County	6,779	4,371	64.5
Nevada			
Clark County	9,049	5,797	64.1
New York			
Bronx County	27,306	17,310	63.4
Kings County	25,770	15,749	61.1
New York County	26,113	15,448	59.2
Queens County	15,731	9,653	61.4
North Carolina^b			
Mecklenburg County	5,993	3,891	64.9

Table 3c. HIV viral suppression during 2020 (COVID-19 pandemic) among persons aged ≥ 13 years with HIV infection diagnosed by year-end 2019 and alive at year-end 2020, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*cont*)

Area of residence	Persons alive at year-end 2020	VL <200 copies/mL	
	No.	No.	%
Ohio			
Cuyahoga County	4,737	3,118	65.8
Franklin County	5,003	3,309	66.1
Hamilton County	2,987	1,862	62.3
Pennsylvania			
Philadelphia County	16,678	9,762	58.5
Tennessee			
Shelby County	6,072	3,939	64.9
Texas			
Bexar County	6,480	4,097	63.2
Dallas County	18,383	10,482	57.0
Harris County	26,174	16,371	62.5
Tarrant County	5,942	3,582	60.3
Travis County	5,006	3,403	68.0
Washington			
King County	6,919	5,516	79.7

Abbreviations: VL, viral load (copies/mL); CD4, CD4+ T-lymphocyte count (cells/ μ L) or percentage [footnotes only]; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on address of residence as of December 31, 2020 (i.e., most recent known address). A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2020. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete lab reporting: Kentucky, Pennsylvania (excluding Philadelphia), Puerto Rico, and Vermont.

^a Data should be interpreted with caution due to incomplete reporting of case information to CDC during December 2021.

^b Data should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2020.

Table 4a. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017 through September 2021, among persons aged ≥ 16 years, by selected characteristics—United States

	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
	2017		
Sex at birth			
Male	144,108	993,840	14.5
Female	11,261	227,240	5.0
Age (yr)			
16–24	19,682	259,130	7.6
25–34	62,820	425,690	14.8
35–44	36,442	233,560	15.6
45–54	24,167	180,870	13.4
≥55	12,300	121,830	10.1
Race/ethnicity^d			
Black/African American	19,647	475,100	4.1
Hispanic/Latino ^e	22,623	299,580	7.6
Other	6,847	132,040	5.2
White	106,351	311,250	34.2
Total	155,468	1,221,080	12.7
	2018		
Sex at birth			
Male	204,722	989,200	20.7
Female	15,872	227,010	7.0
Age (yr)			
16–24	29,821	246,290	12.1
25–34	90,097	434,680	20.7
35–44	51,111	238,470	21.4
45–54	31,556	173,420	18.2
≥55	18,047	123,350	14.6
Race/ethnicity^d			
Black/African American	29,103	468,540	6.2
Hispanic/Latino ^e	33,973	312,820	10.9
Other	9,635	131,180	7.3
White	148,002	300,650	49.2
Total	220,713	1,216,210	18.1
	2019		
Sex at birth			
Male	252,180	989,200	25.5
Female	20,998	227,010	9.2
Age (yr)			
16–24	36,867	246,290	15.0
25–34	112,015	434,680	25.8
35–44	63,290	238,470	26.5
45–54	36,906	173,420	21.3
≥55	24,157	123,350	19.6
Race/ethnicity^d			
Black/African American	37,084	468,540	7.9
Hispanic/Latino ^e	43,334	312,820	13.9
Other	11,649	131,180	8.9
White	181,255	300,650	60.3
Total	273,321	1,216,210	22.5

Table 4a. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017 through September 2021, among persons aged ≥ 16 years, by selected characteristics—United States (cont)

	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
2020 (COVID-19 pandemic)			
Sex at birth			
Male	276,810	989,200	28.0
Female	23,667	227,010	10.4
Age (yr)			
16–24	38,420	246,290	15.6
25–34	119,125	434,680	27.4
35–44	72,044	238,470	30.2
45–54	40,603	173,420	23.4
≥55	30,313	123,350	24.6
Race/ethnicity^d			
Black/African American	42,568	468,540	9.1
Hispanic/Latino ^e	49,306	312,820	15.8
Other	12,254	131,180	9.3
White	196,478	300,650	65.4
Total	300,606	1,216,210	24.7
2021 (January–September)			
Sex at birth			
Male	293,764	989,200	29.7
Female	22,994	227,010	10.1
Age (yr)			
16–24	38,462	246,290	15.6
25–34	126,174	434,680	29.0
35–44	78,257	238,470	32.8
45–54	41,124	173,420	23.7
≥55	32,927	123,350	26.7
Race/ethnicity^d			
Black/African American	44,351	468,540	9.5
Hispanic/Latino ^e	52,750	312,820	16.9
Other	12,825	131,180	9.8
White	207,180	300,650	68.9
Total	317,106	1,216,210	26.1

Abbreviations: PrEP, preexposure prophylaxis; FDA, Food and Drug Administration [footnotes only].

Note. Data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/ local jurisdictions.

^a Estimated by using data from IQVIA pharmacy database reported through September 2021 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported; thus, values may not sum to column total.

^b Estimated by using 2017 and 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. In this table, 2017 denominators were used for 2017 PrEP coverage data; 2018 denominators were used for 2018–2021 PrEP coverage data.

^c PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

^d Race/ethnicity data were only available for <40% of persons prescribed PrEP in each year. Number prescribed PrEP and PrEP coverage for race/ ethnicity reported in the table were adjusted applying the distribution of records with known race/ethnicity to records with missing race/ethnicity.

^e Hispanic/Latino persons can be of any race.

Table 4b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017 through September 2021, among persons aged ≥ 16 years, by area of residence—United States and Puerto Rico

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
	2017		
Alabama	1,017	11,390	8.9
Alaska	126	2,370	5.3
Arizona	2,252	26,820	8.4
Arkansas	418	4,840	8.6
California	26,160	166,150	15.7
Colorado	2,392	25,510	9.4
Connecticut	1,578	10,970	14.4
Delaware	281	4,860	5.8
District of Columbia	3,807	13,710	27.8
Florida	8,449	125,160	6.8
Georgia	4,483	40,680	11.0
Hawaii	442	5,440	8.1
Idaho	265	3,860	6.9
Illinois	10,157	54,620	18.6
Indiana	1,550	21,640	7.2
Iowa	770	4,280	18.0
Kansas	523	5,570	9.4
Kentucky	756	13,170	5.7
Louisiana	2,187	15,490	14.1
Maine	312	3,270	9.5
Maryland	2,709	28,150	9.6
Massachusetts	5,500	25,110	21.9
Michigan	2,260	28,520	7.9
Minnesota	2,510	23,770	10.6
Mississippi	472	5,030	9.4
Missouri	1,890	19,420	9.7
Montana	121	2,750	4.4
Nebraska	351	2,590	13.6
Nevada	1,054	10,870	9.7
New Hampshire	321	3,110	10.3
New Jersey	3,299	28,590	11.5
New Mexico	610	6,720	9.1
New York	22,571	74,450	30.3
North Carolina	2,577	33,110	7.8
North Dakota	109	1,230	8.9
Ohio	3,500	40,940	8.5
Oklahoma	532	11,030	4.8
Oregon	2,042	20,720	9.9
Pennsylvania	6,110	36,160	16.9
Puerto Rico	127	9,700	1.3
Rhode Island	632	4,360	14.5
South Carolina	712	10,390	6.9
South Dakota	54	1,000	5.4
Tennessee	1,719	22,890	7.5
Texas	11,093	123,400	9.0
Utah	1,049	6,900	15.2
Vermont	219	1,490	14.7
Virginia	2,052	33,670	6.1
Washington	6,334	35,600	17.8
West Virginia	235	3,660	6.4
Wisconsin	1,288	14,230	9.1
Wyoming	49	1,410	3.5

Table 4b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017 through September 2021, among persons aged ≥ 16 years, by area of residence—United States and Puerto Rico (cont)

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
	2018		
Alabama	1,543	11,020	14.0
Alaska	198	1,780	11.1
Arizona	3,510	25,780	13.6
Arkansas	590	5,130	11.5
California	36,033	165,030	21.8
Colorado	3,434	25,120	13.7
Connecticut	2,265	9,560	23.7
Delaware	423	4,400	9.6
District of Columbia	5,017	12,950	38.7
Florida	14,711	125,330	11.7
Georgia	6,332	39,030	16.2
Hawaii	679	4,360	15.6
Idaho	364	4,790	7.6
Illinois	13,886	55,860	24.9
Indiana	2,199	22,170	9.9
Iowa	1,152	4,760	24.2
Kansas	726	5,060	14.3
Kentucky	1,215	12,990	9.4
Louisiana	3,318	15,920	20.8
Maine	495	3,950	12.5
Maryland	3,977	27,300	14.6
Massachusetts	7,616	24,900	30.6
Michigan	3,496	29,570	11.8
Minnesota	3,482	21,720	16.0
Mississippi	656	4,530	14.5
Missouri	2,737	18,370	14.9
Montana	185	2,290	8.1
Nebraska	475	2,180	21.8
Nevada	1,489	11,390	13.1
New Hampshire	500	3,020	16.6
New Jersey	4,619	25,280	18.3
New Mexico	810	6,800	11.9
New York	30,105	72,640	41.4
North Carolina	4,014	32,490	12.4
North Dakota	161	1,520	10.6
Ohio	4,785	40,320	11.9
Oklahoma	813	11,030	7.4
Oregon	2,751	19,750	13.9
Pennsylvania	8,553	36,490	23.4
Puerto Rico	237	9,700	2.4
Rhode Island	866	3,880	22.3
South Carolina	1,251	10,390	12.0
South Dakota	99	910	10.9
Tennessee	2,609	22,460	11.6
Texas	17,731	123,790	14.3
Utah	1,489	6,840	21.8
Vermont	281	1,060	26.5
Virginia	3,140	31,430	10.0
Washington	8,236	40,050	20.6
West Virginia	372	5,250	7.1
Wisconsin	1,856	12,980	14.3
Wyoming	71	890	8.0

Table 4b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017 through September 2021, among persons aged ≥ 16 years, by area of residence—United States and Puerto Rico (cont)

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
	2019		
Alabama	1,834	11,020	16.6
Alaska	229	1,780	12.9
Arizona	4,550	25,780	17.6
Arkansas	732	5,130	14.3
California	41,473	165,030	25.1
Colorado	4,336	25,120	17.3
Connecticut	2,656	9,560	27.8
Delaware	473	4,400	10.8
District of Columbia	5,817	12,950	44.9
Florida	21,670	125,330	17.3
Georgia	8,584	39,030	22.0
Hawaii	812	4,360	18.6
Idaho	471	4,790	9.8
Illinois	16,572	55,860	29.7
Indiana	2,962	22,170	13.4
Iowa	1,419	4,760	29.8
Kansas	898	5,060	17.7
Kentucky	1,614	12,990	12.4
Louisiana	3,920	15,920	24.6
Maine	638	3,950	16.2
Maryland	4,928	27,300	18.1
Massachusetts	9,265	24,900	37.2
Michigan	4,361	29,570	14.7
Minnesota	4,178	21,720	19.2
Mississippi	940	4,530	20.8
Missouri	3,465	18,370	18.9
Montana	267	2,290	11.7
Nebraska	617	2,180	28.3
Nevada	2,163	11,390	19.0
New Hampshire	617	3,020	20.4
New Jersey	5,660	25,280	22.4
New Mexico	1,074	6,800	15.8
New York	35,001	72,640	48.2
North Carolina	5,370	32,490	16.5
North Dakota	193	1,520	12.7
Ohio	6,105	40,320	15.1
Oklahoma	1,146	11,030	10.4
Oregon	3,372	19,750	17.1
Pennsylvania	10,111	36,490	27.7
Puerto Rico	330	9,700	3.4
Rhode Island	1,084	3,880	27.9
South Carolina	1,726	10,390	16.6
South Dakota	148	910	16.3
Tennessee	3,886	22,460	17.3
Texas	22,989	123,790	18.6
Utah	2,018	6,840	29.5
Vermont	337	1,060	31.8
Virginia	4,389	31,430	14.0
Washington	9,823	40,050	24.5
West Virginia	568	5,250	10.8
Wisconsin	2,462	12,980	19.0
Wyoming	94	890	10.6

Table 4b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017 through September 2021, among persons aged ≥ 16 years, by area of residence—United States and Puerto Rico (cont)

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
	2020 (COVID-19 pandemic)		
Alabama	1,918	11,020	17.4
Alaska	244	1,780	13.7
Arizona	5,051	25,780	19.6
Arkansas	870	5,130	17.0
California	42,304	165,030	25.6
Colorado	4,765	25,120	19.0
Connecticut	2,477	9,560	25.9
Delaware	467	4,400	10.6
District of Columbia	5,953	12,950	46.0
Florida	34,581	125,330	27.6
Georgia	9,745	39,030	25.0
Hawaii	903	4,360	20.7
Idaho	660	4,790	13.8
Illinois	15,938	55,860	28.5
Indiana	3,198	22,170	14.4
Iowa	1,516	4,760	31.8
Kansas	944	5,060	18.7
Kentucky	1,668	12,990	12.8
Louisiana	3,603	15,920	22.6
Maine	663	3,950	16.8
Maryland	4,798	27,300	17.6
Massachusetts	9,372	24,900	37.6
Michigan	4,687	29,570	15.9
Minnesota	4,190	21,720	19.3
Mississippi	1,098	4,530	24.2
Missouri	3,570	18,370	19.4
Montana	299	2,290	13.1
Nebraska	725	2,180	33.3
Nevada	2,496	11,390	21.9
New Hampshire	649	3,020	21.5
New Jersey	5,921	25,280	23.4
New Mexico	1,237	6,800	18.2
New York	34,090	72,640	46.9
North Carolina	6,160	32,490	19.0
North Dakota	216	1,520	14.2
Ohio	6,833	40,320	16.9
Oklahoma	1,524	11,030	13.8
Oregon	3,819	19,750	19.3
Pennsylvania	10,608	36,490	29.1
Puerto Rico	368	9,700	3.8
Rhode Island	1,153	3,880	29.7
South Carolina	2,120	10,390	20.4
South Dakota	144	910	15.8
Tennessee	5,168	22,460	23.0
Texas	27,520	123,790	22.2
Utah	2,370	6,840	34.6
Vermont	321	1,060	30.3
Virginia	5,131	31,430	16.3
Washington	10,025	40,050	25.0
West Virginia	522	5,250	9.9
Wisconsin	2,521	12,980	19.4
Wyoming	99	890	11.1

Table 4b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017 through September 2021, among persons aged ≥ 16 years, by area of residence—United States and Puerto Rico (cont)

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
	2021 (January–September)		
Alabama	2,387	11,020	21.7
Alaska	255	1,780	14.3
Arizona	5,690	25,780	22.1
Arkansas	1,096	5,130	21.4
California	43,451	165,030	26.3
Colorado	5,238	25,120	20.9
Connecticut	2,532	9,560	26.5
Delaware	547	4,400	12.4
District of Columbia	6,062	12,950	46.8
Florida	36,017	125,330	28.7
Georgia	10,743	39,030	27.5
Hawaii	966	4,360	22.2
Idaho	725	4,790	15.1
Illinois	16,143	55,860	28.9
Indiana	3,708	22,170	16.7
Iowa	1,611	4,760	33.8
Kansas	1,083	5,060	21.4
Kentucky	1,898	12,990	14.6
Louisiana	3,670	15,920	23.1
Maine	772	3,950	19.5
Maryland	5,063	27,300	18.5
Massachusetts	8,641	24,900	34.7
Michigan	5,131	29,570	17.4
Minnesota	4,509	21,720	20.8
Mississippi	1,407	4,530	31.1
Missouri	3,659	18,370	19.9
Montana	344	2,290	15.0
Nebraska	842	2,180	38.6
Nevada	4,308	11,390	37.8
New Hampshire	690	3,020	22.8
New Jersey	6,264	25,280	24.8
New Mexico	1,378	6,800	20.3
New York	33,948	72,640	46.7
North Carolina	6,854	32,490	21.1
North Dakota	235	1,520	15.5
Ohio	7,427	40,320	18.4
Oklahoma	2,004	11,030	18.2
Oregon	3,991	19,750	20.2
Pennsylvania	11,458	36,490	31.4
Puerto Rico	485	9,700	5.0
Rhode Island	1,329	3,880	34.3
South Carolina	2,549	10,390	24.5
South Dakota	179	910	19.7
Tennessee	6,330	22,460	28.2
Texas	30,482	123,790	24.6
Utah	2,865	6,840	41.9
Vermont	415	1,060	39.2
Virginia	5,438	31,430	17.3
Washington	9,898	40,050	24.7
West Virginia	612	5,250	11.7
Wisconsin	2,398	12,980	18.5
Wyoming	117	890	13.1

Abbreviations: PrEP, preexposure prophylaxis; FDA, Food and Drug Administration [footnotes only].

Note. Data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

^a Estimated by using data from IQVIA pharmacy database reported through September 2021 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported; thus, values may not sum to column total.

^b Estimated by using 2017 and 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. In this table, 2017 denominators were used for 2017 PrEP coverage data; 2018 denominators were used for 2018–2021 PrEP coverage data.

^c PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

^d Number of persons with PrEP indications in Puerto Rico is not available in 2017. Number of persons with PrEP indications in 2018 is used for 2017 denominator.

Table 4c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017 through September 2021, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
	2017		
Arizona			
Maricopa County	1,796	23,540	7.6
California			
Alameda County	1,412	7,260	19.4
Los Angeles County	8,668	64,180	13.5
Orange County	1,052	9,990	10.5
Riverside County	979	11,040	8.9
Sacramento County	579	5,460	10.6
San Bernardino County	375	12,450	3.0
San Diego County	2,348	19,420	12.1
San Francisco County	6,293	11,330	55.5
District of Columbia	3,807	13,710	27.8
Florida			
Broward County	1,938	20,030	9.7
Duval County	249	9,250	2.7
Hillsborough County	602	12,670	4.8
Miami-Dade County	1,937	22,190	8.7
Orange County	1,003	16,500	6.1
Palm Beach County	371	7,620	4.9
Pinellas County	472	10,470	4.5
Georgia			
Cobb County	269	3,570	7.5
DeKalb County	872	6,370	13.7
Fulton County	1,915	12,060	15.9
Gwinnett County	312	3,390	9.2
Illinois			
Cook County	8,519	38,270	22.3
Indiana			
Marion County	682	8,490	8.0
Louisiana			
East Baton Rouge Parish	222	1,290	17.2
Orleans Parish	856	5,230	16.4
Maryland			
Baltimore City	464	6,000	7.7
Montgomery County	522	5,790	9.0
Prince George's County	453	3,830	11.8
Massachusetts			
Suffolk County	1,671	7,050	23.7
Michigan			
Wayne County	681	9,470	7.2
Nevada			
Clark County	896	8,790	10.2
New Jersey			
Essex County	393	5,190	7.6
Hudson County	633	4,720	13.4

Table 4c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017 through September 2021, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*cont*)

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
	2017 (<i>cont</i>)		
New York			
Bronx County	1,297	6,690	19.4
Kings County	4,746	15,300	31.0
New York County	9,473	14,790	64.1
Queens County	2,518	8,740	28.8
North Carolina			
Mecklenburg County	649	9,430	6.9
Ohio			
Cuyahoga County	596	8,200	7.3
Franklin County	1,315	13,660	9.6
Hamilton County	263	6,430	4.1
Pennsylvania			
Philadelphia County	2,369	8,550	27.7
Puerto Rico			
San Juan Municipio ^d	— ^e	2,190	n/a
Tennessee			
Shelby County	304	7,590	4.0
Texas			
Bexar County	665	13,010	5.1
Dallas County	2,123	22,000	9.7
Harris County	2,529	39,780	6.4
Tarrant County	658	11,550	5.7
Travis County	2,200	10,810	20.4
Washington			
King County	4,571	13,690	33.4

Table 4c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017 through September 2021, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*cont*)

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
	2018		
Arizona			
Maricopa County	2,813	22,720	12.4
California			
Alameda County	1,858	8,930	20.8
Los Angeles County	12,111	67,450	18.0
Orange County	1,607	10,510	15.3
Riverside County	1,410	11,080	12.7
Sacramento County	786	5,920	13.3
San Bernardino County	605	11,890	5.1
San Diego County	3,364	14,500	23.2
San Francisco County	7,862	10,840	72.5
District of Columbia	5,017	12,950	38.7
Florida			
Broward County	2,859	20,470	14.0
Duval County	373	8,970	4.2
Hillsborough County	1,087	12,910	8.4
Miami-Dade County	3,821	21,760	17.6
Orange County	1,864	15,310	12.2
Palm Beach County	578	9,170	6.3
Pinellas County	808	9,530	8.5
Georgia			
Cobb County	384	3,070	12.5
DeKalb County	1,190	6,290	18.9
Fulton County	2,578	13,120	19.6
Gwinnett County	457	3,240	14.1
Illinois			
Cook County	11,440	39,060	29.3
Indiana			
Marion County	864	9,150	9.4
Louisiana			
East Baton Rouge Parish	439	1,810	24.3
Orleans Parish	1,198	4,590	26.1
Maryland			
Baltimore City	653	6,330	10.3
Montgomery County	766	5,770	13.3
Prince George's County	667	4,040	16.5
Massachusetts			
Suffolk County	2,218	6,520	34.0
Michigan			
Wayne County	1,022	9,270	11.0
Nevada			
Clark County	1,250	11,670	10.7
New Jersey			
Essex County	578	4,090	14.1
Hudson County	866	4,650	18.6

Table 4c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017 through September 2021, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*cont*)

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
	2018 (<i>cont</i>)		
New York			
Bronx County	2,009	5,570	36.1
Kings County	6,324	15,650	40.4
New York County	12,162	15,540	78.3
Queens County	3,276	9,230	35.5
North Carolina			
Mecklenburg County	959	8,450	11.3
Ohio			
Cuyahoga County	810	7,520	10.8
Franklin County	1,640	11,620	14.1
Hamilton County	438	7,720	5.7
Pennsylvania			
Philadelphia County	3,235	9,840	32.9
Puerto Rico			
San Juan Municipio	— ^e	2,190	n/a
Tennessee			
Shelby County	460	6,450	7.1
Texas			
Bexar County	1,131	11,920	9.5
Dallas County	3,241	28,670	11.3
Harris County	3,949	40,670	9.7
Tarrant County	1,173	11,340	10.3
Travis County	3,375	11,590	29.1
Washington			
King County	5,786	17,890	32.3

Table 4c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017 through September 2021, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*cont*)

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
	2019		
Arizona			
Maricopa County	3,520	22,720	15.5
California			
Alameda County	2,163	8,930	24.2
Los Angeles County	13,681	67,450	20.3
Orange County	2,028	10,510	19.3
Riverside County	1,765	11,080	15.9
Sacramento County	947	5,920	16.0
San Bernardino County	751	11,890	6.3
San Diego County	3,700	14,500	25.5
San Francisco County	8,785	10,840	81.0
District of Columbia	5,817	12,950	44.9
Florida			
Broward County	3,766	20,470	18.4
Duval County	503	8,970	5.6
Hillsborough County	1,374	12,910	10.6
Miami-Dade County	6,498	21,760	29.9
Orange County	2,764	15,310	18.1
Palm Beach County	874	9,170	9.5
Pinellas County	1,119	9,530	11.7
Georgia			
Cobb County	556	3,070	18.1
DeKalb County	1,548	6,290	24.6
Fulton County	3,270	13,120	24.9
Gwinnett County	675	3,240	20.8
Illinois			
Cook County	13,544	39,060	34.7
Indiana			
Marion County	1,123	9,150	12.3
Louisiana			
East Baton Rouge Parish	489	1,810	27.0
Orleans Parish	1,509	4,590	32.9
Maryland			
Baltimore City	897	6,330	14.2
Montgomery County	892	5,770	15.5
Prince George's County	813	4,040	20.1
Massachusetts			
Suffolk County	2,749	6,520	42.2
Michigan			
Wayne County	1,201	9,270	13.0
Nevada			
Clark County	1,849	11,670	15.8
New Jersey			
Essex County	673	4,090	16.5
Hudson County	1,046	4,650	22.5

Table 4c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017 through September 2021, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*cont*)

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
	2019 (<i>cont</i>)		
New York			
Bronx County	2,214	5,570	39.7
Kings County	7,487	15,650	47.8
New York County	13,953	15,540	89.8
Queens County	3,819	9,230	41.4
North Carolina			
Mecklenburg County	1,340	8,450	15.9
Ohio			
Cuyahoga County	949	7,520	12.6
Franklin County	2,039	11,620	17.5
Hamilton County	559	7,720	7.2
Pennsylvania			
Philadelphia County	3,647	9,840	37.1
Puerto Rico			
San Juan Municipio	— ^e	2,190	n/a
Tennessee			
Shelby County	632	6,450	9.8
Texas			
Bexar County	1,497	11,920	12.6
Dallas County	4,062	28,670	14.2
Harris County	4,901	40,670	12.1
Tarrant County	1,452	11,340	12.8
Travis County	4,543	11,590	39.2
Washington			
King County	6,878	17,890	38.4

Table 4c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017 through September 2021, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*cont*)

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
	2020 (COVID-19 pandemic)		
Arizona			
Maricopa County	3,888	22,720	17.1
California			
Alameda County	2,029	8,930	22.7
Los Angeles County	14,796	67,450	21.9
Orange County	2,218	10,510	21.1
Riverside County	1,913	11,080	17.3
Sacramento County	967	5,920	16.3
San Bernardino County	816	11,890	6.9
San Diego County	3,767	14,500	26.0
San Francisco County	8,085	10,840	74.6
District of Columbia	5,953	12,950	46.0
Florida			
Broward County	6,711	20,470	32.8
Duval County	742	8,970	8.3
Hillsborough County	1,516	12,910	11.7
Miami-Dade County	10,284	21,760	47.3
Orange County	3,870	15,310	25.3
Palm Beach County	3,015	9,170	32.9
Pinellas County	1,214	9,530	12.7
Georgia			
Cobb County	643	3,070	20.9
DeKalb County	1,712	6,290	27.2
Fulton County	3,573	13,120	27.2
Gwinnett County	787	3,240	24.3
Illinois			
Cook County	12,861	39,060	32.9
Indiana			
Marion County	1,199	9,150	13.1
Louisiana			
East Baton Rouge Parish	528	1,810	29.2
Orleans Parish	1,341	4,590	29.2
Maryland			
Baltimore City	854	6,330	13.5
Montgomery County	902	5,770	15.6
Prince George's County	823	4,040	20.4
Massachusetts			
Suffolk County	2,804	6,520	43.0
Michigan			
Wayne County	1,225	9,270	13.2
Nevada			
Clark County	2,095	11,670	18.0
New Jersey			
Essex County	706	4,090	17.3
Hudson County	1,050	4,650	22.6

Table 4c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017 through September 2021, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*cont*)

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
	2020 (COVID-19 pandemic) (<i>cont</i>)		
New York			
Bronx County	2,043	5,570	36.7
Kings County	7,411	15,650	47.4
New York County	13,669	15,540	88.0
Queens County	3,787	9,230	41.0
North Carolina			
Mecklenburg County	1,571	8,450	18.6
Ohio			
Cuyahoga County	961	7,520	12.8
Franklin County	2,317	11,620	19.9
Hamilton County	630	7,720	8.2
Pennsylvania			
Philadelphia County	3,489	9,840	35.5
Puerto Rico			
San Juan Municipio	— ^e	2,190	n/a
Tennessee			
Shelby County	810	6,450	12.6
Texas			
Bexar County	1,767	11,920	14.8
Dallas County	5,172	28,670	18.0
Harris County	5,966	40,670	14.7
Tarrant County	1,650	11,340	14.6
Travis County	5,076	11,590	43.8
Washington			
King County	6,971	17,890	39.0

Table 4c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017 through September 2021, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*cont*)

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
	2021 (January–September)		
Arizona			
Maricopa County	4,373	22,720	19.2
California			
Alameda County	1,895	8,930	21.2
Los Angeles County	15,970	67,450	23.7
Orange County	2,476	10,510	23.6
Riverside County	2,138	11,080	19.3
Sacramento County	933	5,920	15.8
San Bernardino County	999	11,890	8.4
San Diego County	3,790	14,500	26.1
San Francisco County	7,269	10,840	67.1
District of Columbia	6,062	12,950	46.8
Florida			
Broward County	6,982	20,470	34.1
Duval County	767	8,970	8.6
Hillsborough County	1,689	12,910	13.1
Miami-Dade County	9,869	21,760	45.4
Orange County	4,101	15,310	26.8
Palm Beach County	2,361	9,170	25.7
Pinellas County	1,411	9,530	14.8
Georgia			
Cobb County	698	3,070	22.7
DeKalb County	1,840	6,290	29.3
Fulton County	3,825	13,120	29.2
Gwinnett County	866	3,240	26.7
Illinois			
Cook County	12,971	39,060	33.2
Indiana			
Marion County	1,410	9,150	15.4
Louisiana			
East Baton Rouge Parish	520	1,810	28.7
Orleans Parish	1,345	4,590	29.3
Maryland			
Baltimore City	866	6,330	13.7
Montgomery County	988	5,770	17.1
Prince George's County	882	4,040	21.8
Massachusetts			
Suffolk County	2,385	6,520	36.6
Michigan			
Wayne County	1,337	9,270	14.4
Nevada			
Clark County	3,816	11,670	32.7
New Jersey			
Essex County	724	4,090	17.7
Hudson County	1,100	4,650	23.7

Table 4c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017 through September 2021, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*cont*)

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
	2021 (January–September) (<i>cont</i>)		
New York			
Bronx County	1,820	5,570	32.7
Kings County	7,649	15,650	48.9
New York County	13,880	15,540	89.3
Queens County	3,695	9,230	40.0
North Carolina			
Mecklenburg County	1,712	8,450	20.3
Ohio			
Cuyahoga County	1,091	7,520	14.5
Franklin County	2,448	11,620	21.1
Hamilton County	698	7,720	9.0
Pennsylvania			
Philadelphia County	3,524	9,840	35.8
Puerto Rico			
San Juan Municipio	50	2,190	2.3
Tennessee			
Shelby County	837	6,450	13.0
Texas			
Bexar County	2,042	11,920	17.1
Dallas County	5,803	28,670	20.2
Harris County	6,607	40,670	16.2
Tarrant County	1,875	11,340	16.5
Travis County	5,204	11,590	44.9
Washington			
King County	6,775	17,890	37.9

Abbreviations: PrEP, preexposure prophylaxis; n/a, not available; FDA, Food and Drug Administration [footnotes only].

Note. Data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

^a Estimated by using data from IQVIA pharmacy database reported through September 2021 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported; thus, values may not sum to column total.

^b Estimated by using 2017 and 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. In this table, 2017 denominators were used for 2017 PrEP coverage data; 2018 denominators were used for 2018–2021 PrEP coverage data.

^c PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

^d Number of persons with PrEP indications in San Jan Municipio is not available in 2017. Number of persons with PrEP indications in 2018 is used for 2017 denominator.

^e Data value <40 was not reported due to unreliability.

Table 5. Ending the HIV Epidemic Phase I jurisdictions

Counties	Territories	States
Arizona	Puerto Rico^a	Alabama
Maricopa County	San Juan Municipio ^a	Arkansas
California		Kentucky ^a
Alameda County		Mississippi
Los Angeles County		Missouri
Orange County		Oklahoma
Riverside County		South Carolina
Sacramento County		
San Bernardino County		
San Diego County		
San Francisco County		
District of Columbia		
Florida		
Broward County		
Duval County		
Hillsborough County		
Miami-Dade County		
Orange County		
Palm Beach County		
Pinellas County		
Georgia		
Cobb County		
DeKalb County		
Fulton County		
Gwinnett County		
Illinois		
Cook County		
Indiana		
Marion County		
Louisiana		
East Baton Rouge Parish		
Orleans Parish		
Maryland		
Baltimore City		
Montgomery County		
Prince George's County		
Massachusetts		
Suffolk County		
Michigan		
Wayne County		
Nevada		
Clark County		
New Jersey^b		
Essex County ^b		
Hudson County ^b		
New York		
Bronx County		
Kings County		
New York County		
Queens County		

Table 5. Ending the HIV Epidemic Phase I jurisdictions (cont)

Counties	Territories	States
North Carolina		
Mecklenburg County		
Ohio		
Cuyahoga County		
Franklin County		
Hamilton County		
Pennsylvania^a		
Philadelphia County		
Tennessee		
Shelby County		
Texas		
Bexar County		
Dallas County		
Harris County		
Tarrant County		
Travis County		
Washington		
King County		

Abbreviations: CDC, the Centers for Disease Control and Prevention [footnotes only]; PrEP, preexposure prophylaxis [footnotes only]; CD4, CD4+ T-lymphocyte count (cells/ μ L) or percentage [footnotes only].

Note. For more information on the Ending the HIV Epidemic in the U.S. initiative, see <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview>.

^a Linkage to care and viral suppression data are not provided for states and associated jurisdictions that have incomplete reporting of laboratory data to CDC: Kentucky, Pennsylvania (excluding Philadelphia), Puerto Rico, and Vermont.

^b Linkage to care and viral suppression data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral load laboratory results: New Jersey.